176 related articles for article (PubMed ID: 19367397)
1. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.
Levy M; Levi M; Williams MD; Antonelli M; Wang D; Mignini MA
Intensive Care Med; 2009 Jul; 35(7):1196-203. PubMed ID: 19367397
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
[TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
[TBL] [Abstract][Full Text] [Related]
5. Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.
Camporota L; Corno E; Menaldo E; Smith J; Lei K; Beale R; Wyncoll D
Crit Care; 2008; 12(6):R163. PubMed ID: 19094233
[TBL] [Abstract][Full Text] [Related]
6. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
McCoy C
Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
[TBL] [Abstract][Full Text] [Related]
7. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
Dhainaut JF;
Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
[TBL] [Abstract][Full Text] [Related]
8. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
[TBL] [Abstract][Full Text] [Related]
9. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
[TBL] [Abstract][Full Text] [Related]
10. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.
Wheeler A; Steingrub J; Schmidt GA; Sanchez P; Jacobi J; Linde-Zwirble W; Bates B; Qualy RL; Woodward B; Zeckel M
Crit Care Med; 2008 Jan; 36(1):14-23. PubMed ID: 18158435
[TBL] [Abstract][Full Text] [Related]
11. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
[TBL] [Abstract][Full Text] [Related]
12. The safety profile of drotrecogin alfa (activated).
Fumagalli R; Mignini MA
Crit Care; 2007; 11 Suppl 5(Suppl 5):S6. PubMed ID: 18269693
[TBL] [Abstract][Full Text] [Related]
13. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
Vincent JL; Nadel S; Kutsogiannis DJ; Gibney RT; Yan SB; Wyss VL; Bailey JE; Mitchell CL; Sarwat S; Shinall SM; Janes JM
Crit Care; 2005 Aug; 9(4):R331-43. PubMed ID: 16137345
[TBL] [Abstract][Full Text] [Related]
14. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis.
Goldstein B; Nadel S; Peters M; Barton R; Machado F; Levy H; Haney DJ; Utterback B; Williams MD; Giroir BP
Pediatr Crit Care Med; 2006 May; 7(3):200-11. PubMed ID: 16575354
[TBL] [Abstract][Full Text] [Related]
15. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
Shorr AF; Nelson DR; Wyncoll DL; Reinhart K; Brunkhorst F; Vail GM; Janes J
Crit Care; 2008; 12(2):R45. PubMed ID: 18394162
[TBL] [Abstract][Full Text] [Related]
16. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
[TBL] [Abstract][Full Text] [Related]
17. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
[TBL] [Abstract][Full Text] [Related]
18. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.
Martin G; Brunkhorst FM; Janes JM; Reinhart K; Sundin DP; Garnett K; Beale R
Crit Care; 2009; 13(3):R103. PubMed ID: 19566927
[TBL] [Abstract][Full Text] [Related]
19. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
20. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
